Chiral drugs: The FDA perspective on manufacturing and control
- 10 January 2002
- journal article
- Published by Elsevier
- Vol. 11 (11-12) , 1167-1172
- https://doi.org/10.1016/0731-7085(93)80100-f
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug developmentClinical Pharmacology & Therapeutics, 1992
- Stereochemistry: A source of problems in medicinal chemistryMedicinal Research Reviews, 1986
- Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacologyEuropean Journal of Clinical Pharmacology, 1984
- Broad spectrum resolution of optical isomers using chiral high-performance liquid chromatographic bonded phasesJournal of Chromatography A, 1980
- Chiral high-performance liquid chromatographic stationary phases. 1. Separation of the enantiomers of sulfoxides, amines, amino acids, alcohols, hydroxy acids, lactones, and mercaptansThe Journal of Organic Chemistry, 1979
- The resolution of racemic acid: A classic stereochemical experiment for the undergraduate laboratoryJournal of Chemical Education, 1975
- Liquid chromatographic resolution of racemic β-3,4-dihydroxyphenylalanineJournal of Chromatography A, 1971
- Separation of enantiomers by gas liquid chromatography with an optically active stationary phaseTetrahedron Letters, 1966
- Historical and other considerations regarding the crystal form of sodium-ammonium d - and l -tartrate, potassium d - and l -tartrate, potassium-ammonium d - and l -tartrate, and potassium racemate.—IIAnnals of Science, 1947
- Historical and other considerations regarding the crystal form of sodium-ammonium d - and l -tartrate, potassium d - and l -tartrate, potassium-ammonium d - and l -tartrate, and potassium racemate—IAnnals of Science, 1945